Archive for June, 2010

Global Networks Help Fund Successful Life Science Businesses

Tuesday, June 15th, 2010

A few weeks ago Rowan presented at the excellent Babraham Investment forum in Cambridge, UK. For once we were pitching for hearts and minds instead of cold hard cash for our cause. We were highlighting the need for greater participation of women entrepreneurs in high growth business, and the excellent work of the Global Astia Network.

Astia is a global business network that operates on a lean, not for profit basis. The organisation has an exceptional track record of success (see the presentation below) and one that is well worth bringing to the UK/European market. BioLauncher volunteers time to Astia cause because we regularly encounter clients that have challenges with globalising, funding or scaling their business. A global network can provide the advice and connections to achieve these goals and therefore increase business value. We also recognise that Astia promotes diversity in management teams, so it is not a women only network.

The first Doing IT Right programme and subsequent Astia Investment Forum was held in London in 2009. Helena Kyttari Djupesland, CEO of Optinose was one of our presenters. This week, Optinose secured $48.5M from New York based Avista Capital Partners, a huge success which was well deserved. The deal is also an eloquent demonstration of how European companies need to access the US capital markets.

Next week, the second annual Astia Investment Forum will be held in London. It will be an excellent opportunity to see some of the most promising women led businesses, and meet the Astia executive and advisers. Simon Walker, Chief Executive Officer, British Venture Capital Association will also make a keynote presentation. Bona fide investors can register here.

To keep in touch with the Astia’s development in the UK and keep up to date follow @astiaUK and @vosmek on Twitter of become a friend of Astia on Facebook. Alternatively get in touch with Katie Nittler (Katie@astia.org) who leads the Astia programme in the UK.

Interactive Map of Global Biopharmaceutical Manufacturing Sites

Wednesday, June 9th, 2010

As I posted last week, we have been developing an interactive map of global biopharmaceutical manufacturing and distribution sites. This was originally inspired by a posting in the Professionals in Pharmaceutical Industry and Biotech Industry group on LinkedIn and we have used some of the ShowcaseBio tools to draw together and present the data. We will hopefully be extending this as we get more data and keeping it up to date, so please check back to see how the map develops.

You can see the map here

The data can be sliced and diced by clicking on the boxes below the map, making it easy for example to find API manufacturing sites in Singapore with support for specific bioprocessing procedures and full commercial GMP certification.

Of course this is a fairly basic example of ShowcaseBio’s data integration, analysis and presentation capabilities. We use this regularly on our customer projects to provide rich evidence bases that can be interrogated to define strategy and support real business decisions. We will be posting more examples of some of the work we do with ShowcaseBio in the future on this blog, so keep an eye out.

Global Investment in Bioprocessing 1998-2008

Wednesday, June 2nd, 2010

Mapping Investment in an Industry

A little while ago we were asked to pull together a map of foreign direct investment in bioprocessing capability made around the globe in the previous decade. We wanted to know how difficult it would be for a region to make a difference to the competitiveness of its bioprocessing industrial capacity and skills and what form that intervention might take.

Using a variety of sources from news feeds, web sites, directories and personal information we pulled together the map that you see at the bottom of this article. It became clear pretty quickly that the scale both of the investments and the associated incentives would dwarf anything that could realistically be offered. In total over that decade at least $12B was invested in new plant with approximately $3.6B of declared incentives. Other incentives in the form of tax reliefs, land/plant deals and competitive corporate tax rates would add significantly to this number over the lifetime of the investment.

The data are interesting to play with, and you may know of deals that we missed or that have happened since we did the analysis. The version in this post is just a static image, but there is an interactive version of the map here

The real map is interactive, so you can subselect bits of the information that you are interested in, e.g. just to show fill and finish facilities for small molecule products or manufacturing sites for vaccine production. Just click on the lists at the bottom (underneath the map) to select the bits you are interested in. Click on a spot on the map to find out a bit more about the investment.

I am in the process of pulling together a more complete map of all biopharmaceutical manufacturing and processing facilities as part of a LinkedIn discussion in the Professionals in Pharmaceutical Industry and Biotech Industry group. The good folks there have identified about 500 sites worldwide, and I’ve said I will map them for them once we have sufficient data, so check back in a while for the updated map.

Bioprocessing manufacturing investments from 1998-2008

Bioprocessing manufacturing investments from 1998-2008

Interactive version of the map here